Elderly aortic stenosis patients live longer with minimally invasive valve replacement

Researchers at 21 medical centers followed 358 patients with severe aortic stenosis for five years. The patients, with a mean age of 83, were evenly divided into two study groups -- one that underwent minimally invasive transcatheter aortic valve replacement (TAVR) surgery and one that followed standard therapy, which involved balloon aortic valvuloplasty but no surgery.

Those undergoing TAVR lived longer, with better symptom management, fewer hospital readmissions and better functional status. At the five-year mark, 28.2 percent of the TAVR group were still alive, compared to only 6.4 percent of those undergoing standard therapy.

"This trial is the first--and will probably be the only--randomized aortic stenosis trial that includes a group of patients not treated with aortic valve replacement, since these results will make it unethical to treat severe aortic stenosis patients with medical therapy alone," said Samir Kapadia, M.D., the study's primary author and director of the Sones Cardiac Catheterization Laboratories at Cleveland Clinic.

Aortic stenosis is the most common heart valve disease, causing the aortic valve not to open fully and decreasing blood flow from the heart. For decades, the gold standard treatment was considered aortic valve replacement, though many older patients in their 80s and 90s were considered too sick or too frail to undergo the rigorous surgery. For those patients, TAVR became an option. This study was the first to compare five-year TAVR outcomes with standard therapy.